Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma

Bibliographic Details
Main Authors:	Moran, AM, Ramakrishnan, S, Borg, CA, Connolly, CM, Couillard, S, Mwasuku, CM, Pavord, ID, Hinks, T, Lehtimaki, L
Format:	Journal article
Language:	English
Published:	American Thoracic Society 2020

Similar Items

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
by: Moran, A, et al.
Published: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2017)

Glucocorticoids and mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Mepolizumab in refractory eosinophilic asthma.
by: Pavord, I, et al.
Published: (2010)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
by: Andrea Portacci, et al.
Published: (2023-10-01)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
by: Charlene Desaintjean, et al.
Published: (2024-03-01)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
by: Arian Ghassemian, et al.
Published: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
by: Pavord, I
Published: (2017)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
by: Haldar, P, et al.
Published: (2009)

Mepolizumab for eosinophilic COPD
by: Sciurba, F, et al.
Published: (2018)

Mepolizumab treatment in patients with severe eosinophilic asthma.
by: Ortega, H, et al.
Published: (2014)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
by: Osamu Matsuno, et al.
Published: (2019-01-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
by: Mirhojjat Khorasanizadeh, et al.
Published: (2017-07-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
by: Menzella F, et al.
Published: (2016-06-01)

Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media
by: Satoshi Hamada, et al.
Published: (2021-07-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
by: Gunsoy, N, et al.
Published: (2017)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
by: Yancey, S, et al.
Published: (2016)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
by: Gómez-Bastero Fernández A, et al.
Published: (2022-05-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
by: Stephen G. Noorduyn, et al.
Published: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
by: Francesco Menzella, et al.
Published: (2016-12-01)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
by: Carlos Martínez-Rivera, et al.
Published: (2021-01-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2018)

Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis
by: Stefania Colantuono, et al.
Published: (2020-07-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
by: Steven W. Yancey, et al.
Published: (2019-09-01)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
by: Ortega, H, et al.
Published: (2016)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
by: Andrew Menzies-Gow, et al.
Published: (2019-09-01)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
by: Howell, I, et al.
Published: (2024)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
by: Couillard, S, et al.
Published: (2021)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
by: V. N. Drozdov, et al.
Published: (2020-11-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
by: Takanori Numata, et al.
Published: (2019-10-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
by: Terufumi Shimoda, et al.
Published: (2017-07-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
by: Haldar P
Published: (2017-06-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
by: Ian Pavord, et al.
Published: (2023-04-01)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
by: Pavord, I, et al.
Published: (2017)

Successful Introduction of Benralizumab for Eosinophilic Ascites
by: Nabil Belfeki, et al.
Published: (2024-01-01)

Successful treatment of eosinophilic cystitis with benralizumab
by: W Donald Cooke, et al.
Published: (2020-11-01)

Real-life effects of benralizumab on airway oscillometry in severe eosinophilic asthma
by: Brian J Lipworth, et al.
Published: (2023-12-01)